CD44 and familial pancreatic carcinoma: Cisplatin treatment resulted in an average increase of 77 % in the CD44+CD117+ population, likely because these cells are resistant to cell death from chemotherapy, similar to the enrichment observed in pancreatic cancer ALDH+-expressing cells following cisplatin treatment [6].